BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawanaka M, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, Hiramatsu A, Nishino K, Okamoto T, Sato S, Hara Y, Nishina S, Kawamoto H, Chayama K, Okanoue T, Hino K. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatol Res 2018;48:521-8. [PMID: 29316028 DOI: 10.1111/hepr.13054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Nakai M, Morikawa K, Hosoda S, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, Sakamoto N. Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma. World J Hepatol 2022; 14(7): 1480-1494 [DOI: 10.4254/wjh.v14.i7.1480] [Reference Citation Analysis]
2 Ueno M, Takeda H, Takai A, Seno H. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World J Gastroenterol 2022; 28(27): 3410-3421 [DOI: 10.3748/wjg.v28.i27.3410] [Reference Citation Analysis]
3 Jang SY, Tak WY, Park SY, Kweon YO, Lee YR, Kim G, Hur K, Han MH, Lee WK. Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases. Ann Lab Med 2021;41:302-9. [PMID: 33303715 DOI: 10.3343/alm.2021.41.3.302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Eguchi Y, Wong G, Lee I, Akhtar O, Lopes R, Sumida Y. Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A structured review of published works. Hepatol Res 2021;51:19-30. [DOI: 10.1111/hepr.13583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Ann Lab Med 2021;41:16-24. [PMID: 32829576 DOI: 10.3343/alm.2021.41.1.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
6 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
7 Feng S, Wang Z, Zhao Y, Tao C. Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis. Sci Rep 2020;10:10582. [PMID: 32601332 DOI: 10.1038/s41598-020-67471-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Takemura K, Takizawa E, Tamori A, Nakamae M, Kubota H, Uchida-Kobayashi S, Enomoto M, Kawada N, Hino M. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. Int J Mol Sci 2020;21:E4517. [PMID: 32630450 DOI: 10.3390/ijms21124517] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
10 Liu Y, Li H, Ye N, Luo CJ, Hu YY, Wu H, Gong JP. Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. Med Sci Monit 2019;25:6615-23. [PMID: 31479436 DOI: 10.12659/MSM.915722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Sci Rep 2019;9:10109. [PMID: 31300805 DOI: 10.1038/s41598-019-46172-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
12 Noda Y, Kawaguchi T, Korenaga M, Yoshio S, Komukai S, Nakano M, Niizeki T, Koga H, Kawaguchi A, Kanto T, Torimura T. High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. Hepatol Res 2019;49:1046-53. [PMID: 30993774 DOI: 10.1111/hepr.13350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
13 Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. Hepatol Commun. 2019;3:493-503. [PMID: 30976740 DOI: 10.1002/hep4.1321] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
14 Kanno M, Kawaguchi K, Honda M, Horii R, Takatori H, Shimakami T, Kitamura K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. J Gastroenterol 2019;54:549-57. [PMID: 30707282 DOI: 10.1007/s00535-019-01551-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]